Skip to main content

Table 1 Baseline patient characteristics of patients with AITL receiving first allo-HCT reported to the CIBMTR from 2000 to 2016

From: Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Variable N = 249 (%)
Median age at HCT, years (range) 56 (21–77)
Male gender 150 (60)
Race
 Caucasian 214 (86)
 African American 5 (2)
 Othersa 17 (7)
 Missing 13 (5)
Karnofsky performance score ≥ 90 119 (48)
 < 90 113 (45)
 Missing 17 (7)
HCT-CI
 0 46 (18)
 1–2 53 (21)
 ≥ 3 84 (34)
 Not available before 2007 55 (22)
 Missing 11 (4)
Interval from diagnosis to HCT, months
 Median (range) 14 (3–118)
Median lines of therapy before HCT (range) 3 (1–5)
Remission status at HCT
 Complete remission 108 (43)
 Partial remission 90 (36)
 Chemorefractory 38 (15)
 Untreated/unknown 13 (5)
History of prior autologous HCT 98 (39)
TBI in conditioning 83 (34)
ATG/alemtuzumab in conditioningb 59 (24)
Conditioning intensityc
 Myeloablative conditioning 66 (27)
 Non-myeloablative/RIC 183 (73)
Graft source
 Bone marrow 8 (3)
 Peripheral blood 241 (97)
Donor type
 HLA-identical sibling 140 (56)
 Unrelated donor 8/8 109 (44)
Donor/recipient CMV status
 Both negative 72 (29)
 Both positive 59 (24)
 Either donor/recipient + 69 (28)
 Missing 49 (19)
Graft-versus-host disease prophylaxis
 Calcineurin inhibitor + MTX ± othersd (except MMF) 119 (48)
 Calcineurin inhibitor + MMF ± othersd 76 (31)
 Calcineurin inhibitor + others (except MMF) 40 (16)
 Othersd 10 (4)
 Missing 4 (2)
Year of HCT
 2000–2006 47 (19)
 2007–2011 82 (33)
 2012–2016 120 (48)
Median follow-up of survivors (range), months 49 (4–170)
  1. ATG antithymocyte globulin, CMV cytomegalovirus, HCT hematopoietic cell transplantation, HCT-CI HCT-Comorbidity index, MMF mycophenolate mofetil, MTX methotrexate, TBI total body irradiation, RIC reduced intensity conditioning
  2. aOthers: 13 Asian; 3 Hispanic or Latino; 1 race unspecified, non-Hispanic
  3. bATG/alemtuzumab—49 ATG alone; 10 alemtuzumab alone
  4. cFor details, refer to Additional file 1: Table S4
  5. dFor details, refer to Additional file 1: Table S5